Tesamorelin Research Guide: The Clinically-Proven GHRH Analogue

Among GHRH analogues, tesamorelin stands alone: it completed full clinical development and reached market (as Egrifta) for a specific indication. For laboratory researchers this history translates into something rare — a research reagent with pharmaceutical-grade published data.

Structure

Tesamorelin is the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group on the N-terminus, protecting it from DPP-4 cleavage while preserving native receptor interaction — a light-touch modification compared with the heavier engineering of CJC-1295.

Research value

Depth of documentation. Receptor binding, signalling kinetics, degradation pathways — tesamorelin's literature answers questions other analogues leave open, making it the strongest 'known quantity' for GHRH-receptor work. Our GH-axis comparison article positions it against CJC-1295 and ipamorelin.

Handling and sourcing

Standard lyophilised protocol: -20°C storage, bacteriostatic-water reconstitution, 2-8°C solutions. We stock 5mg and 10mg vials, ≥99% HPLC-verified with batch documentation available on request, express Australia-wide.

Sourcing for a peptide business rather than a single bench? Our wholesale program supplies trade buyers Australia-wide from Australian-sourced, Australian-tested stock.

All compounds discussed are for in-vitro laboratory research only and are not for human or veterinary use.